Axon Enterprise heads into its May 5 Q1 earnings release with short sellers adding positions at the fastest pace in months — a sharp contrast to options markets that remain remarkably calm.
The short-side buildup is the standout heading in. Short interest has climbed 33% in a single week to 4.6% of the free float — and is up 44% over the past month. That is the sharpest one-month acceleration in the data window. The ORTEX short score has ticked up to 42.5, its highest level in the recent history, though it remains well below the danger zone. Borrow conditions, however, tell a different story: cost to borrow is just 0.49% — near rock-bottom — and availability remains loose, meaning the lending market is not under stress. The surge in shares short reflects genuine directional conviction, not a technical squeeze setup.
Options positioning has eased sharply, which makes the short-side build even more striking as a contrast. The put/call ratio is 1.06, barely a rounding error from its 20-day average of 1.07, with a z-score of essentially zero. A month ago the PCR was running above 1.25 — at the defensive extreme of the past year. That hedging pressure has since unwound. The stock is off 5.3% over the past month but has stabilised, closing at $402.31 with a 1.3% gain on the week and RSI at 45 — neither oversold nor extended.
Analysts remain firmly in the bull camp, with all 10 covering firms carrying buy-equivalent ratings. But target prices have been cut broadly since February, with JPMorgan bringing its target down to $750 from $925 as recently as April 16, and Goldman Sachs trimming to $625 from $720 on April 8. The consensus mean target of $708 implies roughly 76% upside from current levels — a gap that reflects the stock's sharp YTD decline of nearly 30%. Bulls point to Axon's growing public safety platform and the potential of Axon 911 as a durable revenue driver. Bears flag the company's reliance on its hardware segment and question whether software and services growth is genuinely accelerating on new customer wins, or simply riding premium subscription upgrades among existing accounts.
Institutional holders are passive and stable — Vanguard and BlackRock together own over 21% with only modest recent changes. Wellington Management added over 1.1 million shares as of March-end, one of the larger active moves in the holder register. Insider activity has been one-directional: the President, Joshua Isner, sold over $8 million of stock in mid-March, and a Chief Level Officer sold another $2.5 million on April 1. No insider buying appears in the 90-day window.
The May 5 print will therefore test whether Axon can demonstrate the kind of software-led revenue beat that its past two quarters delivered — both of which drove immediate 22–24% single-day gains — or whether the accelerating short interest reflects a well-founded view that the stock's current multiple demands a beat-and-raise that proves harder to deliver this cycle.
See the live data behind this article on ORTEX.
Open AXON on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
